CDC Finds One in 400,000 Had Anaphylaxis After Moderna Shot
About one in 400,000 recipients of theModerna Inc. Covid-19 vaccine had a severe allergic reaction to the first shot, according to a study from the U.S. Centers for Disease Control and Prevention released on Friday.
The research, which tracked 10 cases of anaphylaxis among about 4 million doses administered through Jan. 10, concludes that such reactions to the vaccine still appear to be rare. Anaphylaxis to vaccines is uncommon but well-established — with flu shots, for instance, it occurs about 1.3 times per million doses administered, according to CDC officials.
The CDC continues to emphasize the safety of Covid-19 vaccines. It recommends that only those who are allergic to a component of Covid-19 vaccines or who had a severe allergic reaction to an initial dose avoid receiving the shots. The risk of contracting Covid-19 outweighs that posed by the vaccines, officials and clinicians say.
“Early monitoring of both the Moderna and the Pfizer-BioNTech COVID-19 vaccines indicate that anaphylaxis following vaccination is a rare event, and although anaphylaxis is serious, it occurs shortly after vaccination (usually within minutes), is readily diagnosed, and effective treatments are available,” CDC spokeswoman Kristen Nordlund said in an email. “Patients experiencing anaphylaxis after vaccination do well and recover.”
188,952 in U.S.Most new cases today 56,740,891 Vaccine doses administered in 52 countries
+15% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-0.6487 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
